|
|
Article: Synthetic hormone treats precocious puberty. (histrelin acetate)
- Article from:
- FDA Consumer
- Article date:
- March 1, 1992
CopyrightCOPYRIGHT 1992 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A synthetic hormone called histrelin acetate was approved by FDA on Dec. 30, 1991, to treat central, or unexplained, precocious puberty, in which young children develop the sexual characteristics of adolescents.
About 6,000 American children have this condition, with 2,000 new cases diagnosed each year. Histrelin acetate was developed as an orphan product by Ortho Pharmaceuticals of Raritan, N.J., and will be marketed under the brand name Supprelin. Orphan status provides incentives to companies to develop products for use in conditions that afflict fewer than 200,000 people.
In idiopathic central precocious puberty, the most common form of precocious ...